Otsuka Pharmaceutical Co.
Otsuka Pharmaceutical Co., Ltd
2440 Research Boulevard
Rockville, MD 20850
Phone: (301) 990-0030Website: https://www.otsuka-us.com/Careers: www.otsuka-us.com/careers-our-culturePatient Assistance Program: www.otsukapatientassistance.com
Latest news
- FDA Approves Simtriyo (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)
July 24, 2026 - Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety
June 25, 2026 - Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD
May 28, 2026 - Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
January 27, 2026 - FDA Grants Accelerated Approval for Voyxact (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
November 26, 2025 - Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
November 25, 2025 - Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
May 27, 2025 - Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
March 31, 2025 - Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults
November 19, 2024 - Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy
February 16, 2024
Drugs Associated with Otsuka Pharmaceutical Co., Ltd
Otsuka Pharmaceutical Co., Ltd manufactures, markets and/or distributes more than 12 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Abilify
Generic name: aripiprazole Drug class: atypical antipsychotics |
1187 reviews | 6.1 / 10 |
|
Abilify Asimtufii
Generic name: aripiprazole Drug class: atypical antipsychotics |
1 review | 8.0 / 10 |
|
Abilify Maintena
Generic name: aripiprazole Drug class: atypical antipsychotics |
69 reviews | 6.3 / 10 |
|
Busulfex
Generic name: busulfan Drug class: alkylating agents |
||
|
Dacogen
Generic name: decitabine Drug class: antimetabolites |
||
|
Jynarque
Generic name: tolvaptan |
||
|
Neupro
Generic name: rotigotine Drug class: dopaminergic antiparkinsonism agents |
73 reviews | 7.6 / 10 |
|
Nuedexta
Generic name: dextromethorphan/quinidine Drug class: miscellaneous central nervous system agents |
23 reviews | 8.5 / 10 |
|
Rexulti
Generic name: brexpiprazole Drug class: atypical antipsychotics |
488 reviews | 6.6 / 10 |
|
Samsca
Generic name: tolvaptan Drug class: vasopressin antagonists |
||
|
Simtriyo
Generic name: centanafadine |
||
|
Voyxact
Generic name: sibeprenlimab Drug class: miscellaneous uncategorized agents |
10 / 10 | |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
Discontinued Drugs
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Abilify MyCite
Generic name: aripiprazole Drug class: atypical antipsychotics |
||
|
Pletal
Generic name: cilostazol Drug class: miscellaneous cardiovascular agents, platelet aggregation inhibitors |
5 reviews | 6.1 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||